Disease modeling for Ebola and Marburg viruses

被引:134
作者
Bente, Dennis [4 ]
Gren, Jason [4 ]
Strong, James E. [1 ,2 ,4 ]
Feldmann, Heinz [1 ,3 ]
机构
[1] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R2H 2A6, Canada
[2] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R2H 2A6, Canada
[3] NIAID, Virol Lab, Div Intramural Res, NIH, Hamilton, MT 59840 USA
[4] Publ Hlth Agcy Canada, Natl Microbiol Lab, Lab Zoonot Dis & Special Pathogens, Special Pathogens Program, Winnipeg, MB R3E 3R2, Canada
关键词
HEMORRHAGIC-FEVER; EXPERIMENTAL-INFECTION; GUINEA-PIGS; RHESUS-MONKEYS; MOUSE MODEL; PATHOGENESIS; ZAIRE; PROPHYLAXIS; THERAPY; MICE;
D O I
10.1242/dmm.000471
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The filoviruses Ebola and Marburg are zoonotic agents that are classified as both biosafety level 4 and category A list pathogens. These viruses are pathogenic in humans and cause isolated infections or epidemics of viral hemorrhagic fever, mainly in Central Africa. Their natural reservoir has not been definitely identified, but certain species of African bat have been associated with Ebola and Marburg infections. Currently, there are no licensed options available for either treatment or prophylaxis. Different animal models have been developed for filoviruses including mouse, guinea pig and nonhuman primates. The 'gold standard' animal models for pathogenesis, treatment and vaccine studies are rhesus and cynomolgus macaques. This article provides a brief overview of the clinical picture and the pathology/pathogenesis of human filovirus infections. The current animal model options are discussed and compared with regard to their value in different applications. In general, the small animal models, in particular the mouse, are the most feasible for high biocontainment facilities and they offer the most options for research owing to the greater availability of immunologic and genetic tools. However, their mimicry of the human diseases as well as their predictive value for therapeutic efficacy in primates is limited, thereby making them, at best, valuable initial screening tools for pathophysiology, treatment and vaccine studies.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 59 条
[1]  
Aleksandrowicz P, 2008, HAMOSTASEOLOGIE, V28, P77
[2]  
Borisevich IV, 1995, VOP VIRUSOL+, V40, P270
[3]   A COMPARATIVE-STUDY OF STRAINS OF EBOLA VIRUS ISOLATED FROM SOUTHERN SUDAN AND NORTHERN ZAIRE IN 1976 [J].
BOWEN, ETW ;
PLATT, GS ;
LLOYD, G ;
RAYMOND, RT ;
SIMPSON, DIH .
JOURNAL OF MEDICAL VIROLOGY, 1980, 6 (02) :129-138
[4]   EBOLA HEMORRHAGIC-FEVER - EXPERIMENTAL-INFECTION OF MONKEYS [J].
BOWEN, ETW ;
PLATT, GS ;
SIMPSON, DIH ;
MCARDELL, LB ;
RAYMOND, RT .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1978, 72 (02) :188-191
[5]   Lymphocyte death in a mouse model of Ebola virus infection [J].
Bradfute, Steven B. ;
Braun, Denise R. ;
Shamblin, Joshua D. ;
Geisbert, Joan B. ;
Paragas, Jason ;
Garrison, Aura ;
Hensley, Lisa E. ;
Geisbert, Thomas W. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 :S296-S304
[6]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :651-661
[7]   Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus [J].
Bray, M ;
Hatfill, S ;
Hensley, L ;
Huggins, JW .
JOURNAL OF COMPARATIVE PATHOLOGY, 2001, 125 (04) :243-253
[8]   Experimental therapy of filovirus infections [J].
Bray, M ;
Paragas, J .
ANTIVIRAL RESEARCH, 2002, 54 (01) :1-17
[9]   The role of the Type I interferon response in the resistance of mice to filovirus infection [J].
Bray, M .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1365-1373
[10]   AIDS research - Vaccine studies stymied by shortage of animals [J].
Cohen, J .
SCIENCE, 2000, 287 (5455) :959-960